CA2428018A1 - Promedicaments tetrapartates - Google Patents

Promedicaments tetrapartates Download PDF

Info

Publication number
CA2428018A1
CA2428018A1 CA002428018A CA2428018A CA2428018A1 CA 2428018 A1 CA2428018 A1 CA 2428018A1 CA 002428018 A CA002428018 A CA 002428018A CA 2428018 A CA2428018 A CA 2428018A CA 2428018 A1 CA2428018 A1 CA 2428018A1
Authority
CA
Canada
Prior art keywords
compound
substituted
group
moiety
alkyls
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002428018A
Other languages
English (en)
Inventor
Richard B. Greenwald
Hong Zhao
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Enzon Pharmaceuticals Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/758,993 external-priority patent/US6720306B2/en
Application filed by Individual filed Critical Individual
Publication of CA2428018A1 publication Critical patent/CA2428018A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polyethers (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

L'invention concerne un composé de la formule I donnant des promédicaments tétrapartates. L¿1? représente un groupe de liaison bi-fonctionnel; D représente un groupe fonctionnel qui est un groupe partant, ou un résidu d'un composé à administrer dans une cellule; Z est lié de manière covalente à [D]¿y?, Z étant choisi dans le groupe formé d'un groupe fonctionnel activement transporté dans une cellule cible, d'un groupe fonctionnel hydrophobe et de leurs combinaisons; Y¿1?, Y¿2?, Y¿3? et Y¿4? représentent chacun indépendamment O, S, ou NR¿12?; R¿11? représente un résidu polymère mono- ou bivalent; R¿1?, R¿4?, R¿9?, R¿10? et R¿12? sont choisis indépendamment dans le groupe formé d'hydrogène, de C¿1-6? alkyles, de C¿3-12? alkyles ramifiés, de C¿3-8 ?cycloalkyles, de C¿1-6? alkyles substitués, de C¿3-8 ?cycloalkyles substitués, d'aryles, d'aryles substitués, d'aralkyles, de C¿1-6 ?hétéroalkyles et de C¿1-6 ?hétéroalkyles substitués; R¿2?, R¿3?, R¿5? et R¿6 ?sont choisis indépendamment dans le groupe formé d'hydrogène, de C¿1-6? alkyles, de C¿1-6? alcoxy, de phénoxy, de C¿1-8? hétéroalkyles, de C¿1-8? hétéroalcoxy, de C¿1-6? alkyles substitués, de C¿3-8? cycloalkyles, de C¿3-8? cycloalkyles substitués, d'aryles, d'aryles substitués, d'aralkyles, de halo-, de nitro- et cyano-, de carboxy-, de C¿1-6? carboxyalkyles et de C¿1-6? alkylcarbonyles; Ar représente un groupe fonctionnel qui, lorsqu'il intégré dans la formule (I), constitue un hydrocarbure aromatique multi-substitué ou un groupe hétérocyclique multi-substitué; (m), (r), (s), (t) et (u) représentent indépendamment zéro ou un; (p) représente zéro ou un entier positif; et (y) représente 1 ou 2. L'invention concerne également des procédés de préparation et d'utilisation de ces nouveaux promédicaments tétrapartates.
CA002428018A 2000-12-01 2001-11-30 Promedicaments tetrapartates Abandoned CA2428018A1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US72851200A 2000-12-01 2000-12-01
US09/728,512 2000-12-01
US09/758,993 2001-01-12
US09/758,993 US6720306B2 (en) 1997-12-17 2001-01-12 Tetrapartate prodrugs
PCT/US2001/045127 WO2002043663A2 (fr) 2000-12-01 2001-11-30 Promedicaments tetrapartates

Publications (1)

Publication Number Publication Date
CA2428018A1 true CA2428018A1 (fr) 2002-06-06

Family

ID=27111706

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002428018A Abandoned CA2428018A1 (fr) 2000-12-01 2001-11-30 Promedicaments tetrapartates

Country Status (5)

Country Link
EP (1) EP1343494A4 (fr)
JP (1) JP2004518776A (fr)
AU (1) AU2002239405A1 (fr)
CA (1) CA2428018A1 (fr)
WO (1) WO2002043663A2 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6624142B2 (en) * 1997-12-30 2003-09-23 Enzon, Inc. Trimethyl lock based tetrapartate prodrugs
DE60318942T2 (de) * 2002-05-08 2009-02-26 Medical Enzymes Ag Schutzreagenzien enthaltend aktive kohlenhydrate für chemische modifizierungen, deren herstellung und verwendung
WO2005030835A1 (fr) * 2003-09-25 2005-04-07 Terumo Kabushiki Kaisha Derives de polyethylene glycol et vecteurs de medicament contenant ces derives en tant que constituants membranaires
CN100415801C (zh) * 2003-10-28 2008-09-03 北京键凯科技有限公司 聚乙二醇氨基酸n-内环羰酐活性衍生物及其药物键合物和凝胶
CN100543063C (zh) * 2006-04-03 2009-09-23 中国科学院过程工程研究所 氨基酸端基聚乙二醇及其制备方法
WO2008034119A2 (fr) 2006-09-15 2008-03-20 Enzon Pharmaceuticals, Inc. Poly(alkylène oxydes) présentant des segments de liaison biodégradables à base d'ester encombré
AU2007296054B2 (en) * 2006-09-15 2013-03-28 Enzon Pharmaceuticals, Inc. Hindered ester-based biodegradable linkers for oligonucleotide delivery
DE102011118029A1 (de) 2011-06-20 2012-12-20 Universität Leipzig Modifizierte antibiotische Peptide mit variabler systemischer Freisetzung
WO2014075035A1 (fr) 2012-11-12 2014-05-15 Cephalon, Inc. Dérivés de bendamustine et leurs procédés d'utilisation
US10040850B2 (en) 2013-10-08 2018-08-07 Ascendis Pharma A/S Protecting group comprising a purification tag

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9501052D0 (en) * 1995-01-19 1995-03-08 Cancer Res Campaign Tech Improvements relating to prodrugs
EP0751144B1 (fr) * 1995-06-27 2004-10-06 Pharmachemie B.V. Prodrogues anthracyclinen, méthode pour préparation et aussi leur utilisation dans la chémothérapie sélective
CA2312975C (fr) * 1997-12-17 2012-08-21 Enzon, Inc. Prodrogues polymeriques d'agents bioactifs contenant amine ou hydroxy

Also Published As

Publication number Publication date
EP1343494A2 (fr) 2003-09-17
JP2004518776A (ja) 2004-06-24
EP1343494A4 (fr) 2005-08-03
WO2002043663A3 (fr) 2002-07-25
AU2002239405A1 (en) 2002-06-11
WO2002043663A2 (fr) 2002-06-06

Similar Documents

Publication Publication Date Title
US6720306B2 (en) Tetrapartate prodrugs
US6624142B2 (en) Trimethyl lock based tetrapartate prodrugs
US6180095B1 (en) Polymeric prodrugs of amino- and hydroxyl-containing bioactive agents
CA2493329C (fr) Conjugues polymeres liberables fondes sur des lieurs biodegradables aliphatiques
US6303569B1 (en) Trialkyl-lock-facilitated polymeric prodrugs of amino-containing bioactive agents
US7087229B2 (en) Releasable polymeric conjugates based on aliphatic biodegradable linkers
US8192743B2 (en) Releasable polymeric conjugates based on aliphatic biodegradable linkers
US20090203706A1 (en) Lysine-based polymeric linkers
CA2465090C (fr) Promedicaments polymeres a liaison thiol utilisant des systemes d'elimination de benzyle
CA2437989A1 (fr) Lieurs polymeres a terminaisons ramifiees, et conjugues polymeres en contenant
CA2336663C (fr) Coumarine et promedicaments polymeres apparentes a base aromatique
CA2437986A1 (fr) Lieurs polymeriques a ramification terminale et conjugues polymeriques contenant ceux-ci
CA2428018A1 (fr) Promedicaments tetrapartates
ES2331562T3 (es) Profarmacos de agentes anticancerigenos que emplean acidos aromaticos sustituidos.

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead